Estimated cancer risk of dioxins to humans using a bioassay and physiologically based pharmacokinetic model

Toxicology and Applied Pharmacology

Volumn 214, Issue 2, 2006, Pages 188-198

  Maruyama, Wakae ^a   Aoki, Yasunobu ^a  

^a NATIONAL INSTITUTE FOR ENVIRONMENTAL STUDIES   (Japan)

Author keywords

Dioxin; Hepatic foci; PBPK model; Risk assessment

Indexed keywords

1,2,3,7,8 PENTACHLORODIBENZO 4 DIOXIN; 2,3,4,7,8 PENTACHLORODIBENZOFURAN; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; DIOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CANCER RISK; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HEALTH HAZARD; HUMAN; JAPAN; LIVER CANCER; MATHEMATICAL MODEL; NONHUMAN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; QUANTITATIVE ANALYSIS; RAT; RISK ASSESSMENT; SPECIES COMPARISON; TOXICITY TESTING;

EID: 33745683896     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.12.005     Document Type: Article

References (71)

1. Abraham K., Krowke R., and Neubert D. Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Arch. Toxicol. 62 (1988) 359-368
2. Andersen M.E., and Krishnan K. Physiologically based pharmacokinetics and cancer risk assessment. Environ. Health Perspect. 102 Suppl. 1 (1994) 103-108
3. Andersen M.E., Clewell III H.J., Gargas M.L., Smith F.A., and Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87 (1987) 185-205
4. Andersen M.E., Mills J.J., Gargas M.L., Kedderis L., Birnbaum L.S., Neubert D., and Greenlee W.F. Modeling receptor-mediated processes with dioxin: implications of pharmacokinetics and risk assessment. Risk Anal. 13 (1993) 25-36
5. Andersen M.E., Clewell III H., and Krishnan K. Tissue dosimetry, pharmacokinetic modelling, and interspecies scalling factors. Risk Anal. 15 (1995) 533-537
6. Andersen M.E., Birnbaum L.S., Barton H.A., and Eklund C.R. Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation. Toxicol. Appl. Pharmacol. 144 (1997) 145-155
7. Aylward L.L., Lamb J.C., and Lewis S.C. Issues in risk assessment for developmental effects of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin and related compounds. Toxicol. Sci. 87 (2005) 3-10
8. Barton H.A., and Clewell H.J. Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. Environ. Health Perspect. 108 Suppl. 2 (2000) 323-334
9. Barton H.A., and Das S. Alternatives for a risk assessment on chronic noncancer effects from oral exposure to trichloroethylene. Regul. Toxicol. Pharmacol. 24 (1996) 269-285
10. Barton H.A., Andersen M.E., and Allen B.C. Dose-response characteristics of uterine responses in rats exposed to estrogen agonists. Regul. Toxicol. Pharmacol. 28 (1998) 133-149
11. Becher H., Steindorf K., and Flesch-Janys D. Quantitative cancer risk assessment for dioxins using an occupational cohort. Environ. Health Perspect. 106 Suppl. 2 (1998) 663-670
12. Brewster D.W., Uraih L.C., and Birnbaum L.S. The acute toxicity of 2,3,4,7,8-pentachlorodibenzofuran (4PeCDF) in the male Fischer rat. Fundam. Appl. Toxicol. 11 (1988) 236-249
13. Campbell H.A., Pitot H.C., Potter V.R., and Laishes B.A. Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Res. 42 (1982) 465-472
14. Carrier G., Brunet R.C., and Brodeur J. Modelings of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofurans in mammalians, including humans: I. Nonlinear distribution of PCDD/PCDF body burden between liver and adipose tissues. Toxicol. Appl. Pharmacol. 131 (1995) 253-266
15. Chen C.Y., Hamm J.T., Hass J.R., and Birnbaum L.S. Disposition of polychlorinated dibenzo-p-dioxins, dibenzofurans, and non-ortho polychlorinated biphenyls in pregnant Long Evans rats and the transfer to offspring. Toxicol. Appl. Pharmacol. 173 (2001) 65-88
16. Conolly R.B., and Andersen M.E. Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: evaluation of a quantitative two-cell model and of CYP 1A1/1A2 as a dosimeter. Toxicol. Appl. Pharmacol. 146 (1997) 281-293
17. Cox Jr. L.A. Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis. Environ. Health Perspect. 104 Suppl. 6 (1996) 1413-1429
18. Crump K.S. A method for determining allowable daily intakes. Fundam. Appl. Toxicol. 4 (1984) 854-871
19. Crump K.S. Calculation of benchmark doses from continuous data. Risk Anal. 15 (1995) 79-89
20. DeVito M.J., Diliberto J.J., Ross D.G., Menache M.G., and Birnbaum L.S. Dose-response relationships for polyhalogenated dioxins and dibenzofurans following subchronic treatment in mice: I. CYP1A1 and CYP1A2 enzyme activity in liver, lung, and skin. Toxicol. Appl. Pharmacol. 147 (1997) 267-280
21. DeVito M.J., Menache M.G., Diliberto J.J., Ross D.G., and Birnbaum L.S. Dose-response relationships for induction of CYP1A1 and CYP1A2 enzyme activity in liver, lung, and skin in female mice following subchronic exposure to polychlorinated biphenyls. Toxicol. Appl. Pharmacol. 167 (2000) 157-172
22. Dragan Y.P., Xu X.H., Goldworthy H., Maronpot R.R., and Pitot H.C. Characterization of promotion of altered hepatic foci by 2,3,7,8-tetrachlorodibenzo-p-dioxin in the female rat. Carcinogenesis 13 (1992) 1389-1395
23. Easterbrook J., Fackett D., and Li A.P. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4′-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation. Chem.-Biol. Interact. 134 (2001) 243-249
24. Emond C., Birnbaum L.S., and DeVito M.J. Physiologically based pharmacokinetic model for developmental exposures to TCDD in the rat. Toxicol. Sci. 80 (2004) 115-133
25. Environment Agency (Japan), 2000. Report of survey on the exposure of dioxins in humans. [In Japanese]. Retrieved from http://www.env.go.jp/.
26. Fitzgerald D.J., Robinson N.I., and Pester B.A. Application of benzo(a)pyrene and coal tar tumor dose-response data to a modified benchmark dose of guideline development. Environ. Health. Perspect. 112 (2004) 1341-1346
27. Hirakawa H., Iida T., Matsuda T., Tokiwa H., Nagata T., and Nagayama J. Concentrations and distribution of PCDDs, PCDFs and coplanar PCBs in various human tissues. Organohalogen Compd. 10 (1992) 93-96
28. Iida T., Hirakawa H., Matsueda T., Nagayama J., and Nagata T. Polychlorinated dibenzo-p-dioxins and related compounds: correlations of levels in human tissues and in blood. Chemosphere 38 (1999) 2767-2774
29. Ito N., Tsuda H., Tatematsu M., Inoue T., Tagawa Y., Aoki T., Uwagawa S., Kagawa M., Ogiso T., Masui T., Imaida K., Fukushima S., and Asamoto M. Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathion S-transferase placental form foci in rats-An approach for a new medium-term bioassay system. Carcinogenesis 9 (1988) 387-394
30. Ito N., Tatematsu M., Hasegawa R., and Tsuda H. Medium-term bioassay system for detection of carcinogens and modifiers of hepatocarcinogenesis utilizing the GST-P positive liver cell focus as an endpoint marker. Toxicol. Pathol. 17 (1989) 630-641
31. Kim A.H., Kohn M.C., Portier C.J., and Walker N.J. Impact of physiologically based pharmacokinetic modeling on benchmark dose calculations for TCDD-induced biochemical responses. Regul. Toxicol. Pharmacol. 36 (2002) 287-296
32. Kissel J.C., and Robarge G.M. Assessing the elimination of 2,3,7,8-TCDD from humans with a physiologically based pharmacokinetic model. Chemosphere 17 (1988) 2017-2027
33. Kociba R.J., Keyes D.G., Beyer J.E., Carreon R.M., Wade C.E., Dittenber D.A., Kalnins R.P., Frauson L.E., Park C.N., Barnard S.D., Hummel R.R.A., and Humiston C.G. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol. Appl. Pharmacol. 46 (1978) 279-303
34. Kohn M.C., Lucier G.W., Clark G.C., Sewall C., Trischer A.M., and Portier C.J. A mechanistic model of effects of dioxin on gene expression in the rat liver. Toxicol. Appl. Pharmacol. 120 (1993) 138-154
35. Kohn M.C., Lucier G.W., and Portier C.J. The importance of biological realism in dioxin risk assessment models. Risk Anal. 14 (1994) 993-1000
36. Korner W., Golor G., Schulz T., Wiesmuller T., Hagenmaier H., and Neubert D. Tissue concentrations and induction of a hepatic monooxygenase in male Wistar rats after repeated doses of defined polychlorinated dibenzo-p-dioxin and dibenzofuran (PCDDs and PCDFs) mixtures. Arch. Toxicol. 75 (2002) 653-664
37. Landi M.T., Bergen A.W., Baccarelli A., Patterson Jr. D.G., Grassman J., Ter-Minassian M., Mocarelli P., Caporaso N., Masten S.A., Pesatori A.C., Pittman G.S., and Bell D.A. CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy. Toxicology 207 (2005) 191-202
38. Laurent C., Marchand P., Feidt C., Bizec B.L., and Rychen G. Tissue distribution and bioconcentration factors of PCDD/Fs in the liver and adipose tissue following chronic ingestion of contaminated milk in rats. Chemosphere 60 (2005) 929-938
39. Lawrence G.S., and Gobas F.A.P.C. A pharmacokinetic analysis of interspecies extraporation in dioxin risk assessment. Chemosphere 35 (1997) 427-452
40. Leung H.W., Wendling J.M., Orth R., Hileman F., and Paustenbach D. Relative distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in hepatic and adipose tissues. Toxicol. Lett. 50 (1990) 275-282
41. Leung H.W., Paustenbach D.J., Murray F.J., and Andersen M.E. A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. Toxicol. Appl. Pharmacol. 103 (1990) 399-410
42. Liem, A.K.D., Theelen, R.M.C., 1997. Dioxins: chemical analysis, exposure and risk assessment. Ph thesis, National Institute of Public Health and the Environment, P.O. Box 3720 BA, Bilthoven, The Netherlands (Ph.D. Thesis).
43. Luebeck E.G., Buchmann A., Stinchcombe S., Moolgavkar S.H., and Schwarz M. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on initiation and promotion of GST-P-positive foci in rat liver: a quantitative analysis of experimental data using a stochastic model. Toxicol. Appl. Pharmacol. 167 (2000) 63-73
44. Maronpot R.R., Foley J.F., Takahashi K., Goldsworthy T., Clark G., Tritscher A., Portier C., and Lucier G. Dose response for TCDD promotion of hepatocarcinogenesis in rats initiated with DEN: histologic, biochemical, and cell proliferation endpoints. Environ. Health Perspect. 101 (1993) 634-642
45. Maruyama W., Yoshida K., Tanaka T., and Nakanishi J. Possible range of dioxin concentration in human tissues: simulation with a physiological based model. J. Toxicol. Environ. Health, Part A 65 (2002) 2053-2073
46. Maruyama W., Yoshida K., Tanaka T., and Nakanishi J. Simulation of dioxin accumulation in human tissues and analysis of reproductive risk. Chemosphere 53 (2003) 301-313
47. Maruyama W., Tanaka K., and Nakanishi T. Dioxin health risk to infants using simulated tissue concentrations. Environ. Toxicol. Pharmacol. 18 (2004) 21-37
48. Moolgavkar S.H., Luebeck E.G., Buchmann A., and Bock K.W. Quantitative analysis of enzyme-altered liver foci in rats initiated with diethylnitrosamine and promoted with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 138 (1996) 31-42
49. NTP, 2005. TR-521: toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley Rats (gavage studies) (http://www.ntp-server.niehs.nih.gov/).
50. Ou Y.C., Conolly R.B., Thimas R.S., Xu Y., Andersen M.E., Chubb L.S., Pitot H.C., and Yang R.S.H. A clonal growth model: time-course simulation of liver foci growth following panta- or hexachlorobenzene treatment in a medium-term bioassay. Cancer Res. 61 (2001) 879-1889
51. Pitot H.C., Goldsworthy T., Campbell H.A., and Poland A. Quantitative evaluation of the promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin of hepatocarcinogenesis from diethylnitrosoamine. Cancer Res. 40 (1980) 3616-3620
52. Portier C.J., Sherman C.D., Kohn M., Edler L., Kopp-Schneider A., Maronpot R.M., and Lucier G. Modeling the number and size of hepatic focal lesions following exposure to 2,3,7,8-TCDD. Toxicol. Appl. Pharmacol. 138 (1996) 20-30
53. Santostefano M.J., Wang X., Richardson V.M., Ross D.G., DeVito M.J., and Birnbaum L.S. A pharmacodynamic analysis of TCDD-induced cytochrome P450 gene expression in multiple tissues: dose- and time-dependent effects. Toxicol. Appl. Pharmacol. 151 (1998) 294-310
54. Sato K., Kitahara A., Sato K., Ishikawa T., Tatematsu M., and Ito N. The placental form of glutathion S-transferase as a new marker protein for preneoplasia in rat chemical hepatocarcinogenesis. Gann 75 (1984) 199-202
55. Takasuga T., Senthilkumar K., Takemori H., Ohi E., Tsuji H., and Nagayama J. Impact of FEBRA (fermented brown rice with Aspergillus oryzae) intake and concentrations of PCDDs, PCDFs and PCBs in blood of humans from Japan. Chemosphere 57 (2004) 1409-1426
56. Teeguarden J.G., Dragan Y.P., Singh J., Vaughan J., Xu Y.H., Goldsworthy T., and Pitot H.C. Quantitative analysis of dose- and time-dependent promotion of four phenotypes of altered hepatic foci by 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Sprague-Dawley rats. Toxicol. Sci. 51 (1999) 211-223
57. Thoma H., Mucke W., and Kauert G. Comparison of the polychlorinated dibenzo-p-dioxin and dibenzofuran in human tissue and human liver. Chemosphere 20 (1990) 433-442
58. Thomas R.S., Conolly R.B., Gustafson D.L., Long M.E., Benjamin S.A., and Yang R.S.H. A physiologically based pharmacokinetic analysis of hepatic foci within a medium-term liver bioassay using pentachlorobenzene as a promoter and diethylnitrosoamine as an initiator. Toxicol. Appl. Pharmacol. 166 (2000) 128-137
59. Toyoshiba H., Walker N.J., Bailer A.J., and Portier C.J. Evaluation of toxic equivalency factors for induction of cytochromes P450 CYP1A1 and CYP1A2 enzyme activity by dioxin-like compounds. Toxicol. Appl. Pharmacol. 194 (2004) 156-168
60. Tritscher A.M., Goldstein J.A., Portier C.J., McCoy Z., Clark G.C., and Lucier G.W. Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model-Quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. Cancer Res. 52 (1992) 3436-3442
61. Tritscher A.M., Clark G.C., Sewall C., Sills R.C., Maronpot R., and Lucier G.W. Persistence of TCDD-induced hepatic cell proliferation and growth of enzyme altered foci after chronic exposure followed by cessation of treatment in DEN initiated female rats. Carcinogenesis 16 (1995) 2807-2811
62. Tuomisto J. Does mechanistic understanding help in risk assessment-The example of dioxins. Toxicol. Appl. Pharmacol. 207 (2005) S2-S10
63. U.S. Environmental Protection Agency (U.S. EPA), 1999. Guidelines for carcinogen risk assessment. NCEA-F-0644.
64. U.S. Environmental Protection Agency (U.S. EPA), 2000a. Exposure and human health reassessment of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds: Part II. Health assessment for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Chapter 8. EPA/600/P-00/001Be.
65. U.S. Environmental Protection Agency (U.S. EPA), 2000b. Exposure and human health reassessment of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds: Part III. Integrated summary and risk characterization for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. SAB Review Draft. EPA/600/P-00/001Bg.
66. U.S. Environmental Protection Agency (U.S. EPA), 2001. Dioxin reassessment: an SAB review of the office of research and development's reassessment of dioxin. Review of the revised sections (dose response modeling, integrated summary, risk characterization, and toxicity equivalency factors) of the EPA's reassessment of dioxin reassessment review subcommittee of the EPA science advisory board (SAB). EPA-SAB-EC-01-006.
67. Van den Berg M., Birnbaum L., Bosveld A.T.C., Brunstrom B., Cook P., Feeley M., Giesy J.P., Hanberg A., Hasegawa R., Kennedy S.W., Kubiak T., Larsen J.C., Rolaf van Leeuwen F.X., Liem A.K.D., Nolt C., Peterson R.E., Poellinger L., Safe S., Schrenk D., Tillitt D., Tysklind M., Younes M., Waern F., and Zacharewski T. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ. Health Perspect. 106 (1998) 775-792
68. Waern F., Flodstrom S., Busk L., Kronevi T., Nordgren I., and Ahlborg U.G. Relative liver tumour promoting activity and toxicity of some polychlorinated dibenzo-p-dioxin- and dibenzofuran-congeners in female Sprague-Dawley rats. Pharmacol. Toxicol. 69 (1991) 450-458
69. Walker N.J., Crockett P.W., Nyska A., Brix A.E., Jokinen M.P., Sells D.M., Hailey J.R., Easterling M., Haseman J.K., Yin M., Wyde M.E., Bucher J.R., and Portier C.J. Dose-additive carcinogenicity of a defined mixture of "dioxin-like compounds". Environ. Health Perspect. 113 (2005) 43-48
70. Wang X., Santostefano M.J., DeVito M.J., and Birnbaum L.S. Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species. Toxicol.Sci. 56 (2000) 49-60
71. Zeiger M., Haag R., Hockel J., Schrenk D., and Schmitz H.J. Inducing effects of dioxin-like polychlorinated biphenyls on cyp1a in the human hepatoblastoma cell line hepg2, the rat hepatoma cell line H4IIE, and rat primary hepatocytes: comparison of relative potencies. Toxicol. Sci. 63 (2001) 65-73